ArticleDiabetes & vascular disease research
Diabetes mellitus and abdominal aortic aneurysm growth: Clinical evidence and mechanistic insights.
Article in Diabetes & vascular disease research. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BackgroundDiabetes mellitus (DM) has paradoxically been associated with slower abdominal aortic aneurysm (AAA) growth, despite its adverse vascular profile.MethodsWe present a focused synthesis of contemporary longitudinal cohort studies reporting AAA growth rates according to diabetes status and metformin exposure.ResultsAcross six independent cohorts, patients with diabetes consistently exhibited slower aneurysm expansion compared with patients without diabetes, with reported differences of approximately 0.5-1.5 mm/year. Three cohorts further demonstrated that metformin use was independently associated with additional attenuation of AAA growth, with an adjusted reduction of approximately 0.3-0.4 mm/year.ConclusionAvailable clinical evidence consistently supports an inverse association between diabetes and AAA growth, with metformin emerging as a potential disease-modifying factor. These findings highlight metabolic modulation as a promising avenue for individualized surveillance strategies and future therapeutic investigation in AAA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.